Photocure partners with Clinigen on Named Patient Program broadening Access to Hexvix/Cysview (hexaminolevulinate HCl)
Press Release – Oslo, Norway, November 18, 2026: Photocure ASA (OSE: PHO) announces today that it entered into an agreement with Clinigen, for global supply of Hexvix under a Named Patient Program (NPP) starting in 40+ markets in which the product is not yet approved or commercially available through Photocure or one of its distribution partners. Where a physician determines that a bladder cancer patient may benefit from blue light cystoscopy (BLC[®]) with Hexvix[®]/Cysview[® ]in accordance with local laws, and so prescribes this product,[ ]the NPP will enable the supply of Hexvix/Cysview.